Hypnic headache …

Hans-Christoph Diener MD PhD

Headache & Pain

Updated 12.14.2023
Released 06.16.1999
Expires For CME 12.14.2026

Hypnic headache

Author: Hans-Christoph Diener MD PhD

See Contributor Disclosures

Editor: Stephen D Silberstein MD

Hypnic headache

In This Article

Quick Link

Introduction

Overview

Hypnic headache is an uncommon primary headache disorder characterized by relatively short-lived attacks of headache that occur only during sleep, often with striking circadian rhythmicity. This disorder must be distinguished from other primary sleep-associated headaches, such as cluster headache and migraine, as well as secondary mimics. Hypnic headache is more prevalent in the elderly but has been reported to begin much earlier in life. As many patients derive significant benefit from preventative treatment, prompt recognition and management are crucial to prevent unnecessary suffering.

Key points

	• Hypnic headache is a primary headache disorder characterized by short-lived headaches that occur exclusively during sleep.
	• Originally believed to be a disorder of the elderly, subsequent reports suggest that the disorder may begin earlier.
	• Many patients suffer for decades before the diagnosis is made.
	• As with all primary headache disorders, the diagnosis is predicated on exclusion of secondary causes (posterior fossa and pituitary lesions, nocturnal hypertension) and other mimics.
	• Evidence suggests that there may be an associated decrease in gray matter volume in the posterior hypothalamus.
	• First-line therapy is bedtime doses of caffeine; second-line agents include indomethacin or lithium.

Historical note and terminology

Hypnic headache syndrome is a recurrent headache disorder that occurs exclusively during sleep and usually begins after the age of 50 years. This rare syndrome was first characterized by Raskin in 1988, when he described six patients who were awakened regularly from nocturnal sleep by a short-lasting headache (62). Evers and Goadsby’s review, which was published in 2003, reported 71 cases in the literature (21). There are more than 350 cases reported (69), and therapeutic options have expanded (25; 40; 56; 13; 37; 52; 33; 57).

Clinical manifestations

Presentation and course

IHS criteria. The third edition of the International Classification of Headache Disorders officially defines hypnic headache. It is described as “frequently recurring headache attacks developing only during sleep, causing wakening and lasting for up to 4 hours, without characteristic associated symptoms and not attributed to other pathology.” The formal criteria require headaches that 1) develop only during sleep and cause awakening, 2) occur greater than or equal to 10 days per month for greater than or equal to 3 months, 3) last greater than or equal to 15 minutes for up to 4 hours after wakening, and 4) have no associated cranial autonomic symptoms or restlessness. Additionally, the headache should not be accounted for by another ICHD-3 diagnosis. They further clarify that the headache typically starts after age 50 but may occur in younger patients, is not associated with specific stages of sleep, and may have accompanying migrainous features. MRI may show grey matter volume reduction in the hypothalamus. Important changes from the prior ICHD II classification include reduction of the number of required attacks per month from 15 to 10 and the possibility that migrainous features may be present.

Clinical observation reflects several nuances not fully enumerated in the official IHS publication. For example, patients with strictly unilateral headaches, pulsatile headaches, and more severe pain have been reported (21; 41; 19; 37; 52; 33). Although polysomnography is often recommended as part of the evaluation, hypnic headache does not occur strictly during either REM or non-REM sleep. In one small series, 16 out of 23 patients with hypnic headache also had a history of migraine, and in 11 of those 16 cases the migraines disappeared at or prior to the onset of hypnic headaches (64).

Timing. The headache occurs exclusively during sleep; it occurs during daytime hours only when associated with a nap. Some patients report awakening with the headache after a dream. Most patients (51%) experience the attacks between 2:00 A.M. and 4:00 A.M. (69). The headache occurs with striking circadian rhythmicity, with onset at the same time each night (62; 68; 16). This feature has earned it the title of “alarm-clock-headache syndrome.”

Age. Hypnic headache syndrome was originally described as a disorder confined to the elderly. In a larger review, however, the age of onset ranged from 36 to 83 years (21), with a mean of 58 years (69). The pooled mean age of onset of hypnic headache in a meta-analysis of 14 studies was 60.5 years (47). Subsequently, it was reported that hypnic headache can even begin during childhood or adolescence (28; 65; 11). A study of seven children with hypnic headache and a systematic review reported that headache features in children differed from those observed in adult patients (23). Children experienced throbbing and pulsating pain, whereas adults reported dull, pressure-like pain. Children also had lower frequency and shorter duration of attacks compared to adults. Perhaps a long delay in diagnosis is responsible for this mischaracterization; in one study the disorder was present for more than 10 years prior to diagnosis in 36% of patients (19).

Gender. Although five of Raskin’s original six patients were men, the disorder appears to occur equally, if not more commonly, in women. In a 25-patient sample from Brazil, 80% (20 out of 25) patients were women, and diagnosis took an average of 3 +/- 2.7 years from symptom onset (67). In 343 adult patients, 69% were females (69).

Duration. Hypnic headaches usually are short-lasting (30 to 120 min.) but can range from 15 minutes to 3 hours.

Frequency. Sixty four percent of patients usually experience one headache attack per night (69). Some may have recurrent bouts of two or more headaches throughout the night, causing repeated interruption of sleep (62; 55; 68). In over two-thirds of patients, the headaches occur with a high frequency of more than four nights per week; and in some the attacks occur nightly. There is some variability as patients with fewer weekly attacks have also been reported (41; 19).

Two temporal profiles of hypnic headache exist. Most sufferers have a chronic course, but some reports suggest that an episodic form, in which patients have a spontaneous or treatment-induced remissions, may exist (21; 44). A relapsing-remitting variant has also been reported at this point (61).

Intensity. Most headaches are of moderate intensity (61.5%), with up to 33% reaching the severe level (69). Only a small percentage of patients describe their pain as mild. Although headache frequency can vary, the intensity may remain relatively constant or may decrease over time. Pain intensity may be more severe in men (37).

Character. The most common sensation is a dull pain in 75%, occurring in greater than one-half of patients, and up to a third describe the pain as throbbing or pulsating 69). Rarely is it considered sharp or stabbing.

Location. In 50% to 75% of the cases, the pain is bilateral and diffuse (69; 47); however, frontotemporal and unilateral variants with rare posterior predominance have also been described.

Associated symptoms. Individuals may have a previous or coexisting headache history, but hypnic headaches are infrequently associated with migrainous features (eg, photophobia, phonophobia, nausea, or vomiting) and are rarely accompanied by autonomic features (eg, lacrimation, rhinorrhea, or ptosis). Thus, one may distinguish this disorder from cluster headache and migraines that may also occur nocturnally. Literature suggests that patients may engage in typical motor activities (getting up, drinking a cup of coffee, reading, or watching television). These activities also distinguish hypnic headache from migraine, in which patients prefer bedrest, and cluster headache, during which patients are often restless or agitated (16; 21; 44; 19).

Secondary causes. Hypnic headache is a primary headache disorder; however, in several cases presenting as hypnic headache, another secondary cause has been identified including pontine stroke (48), posterior fossa meningioma (58), nonfunctioning pituitary macroadenoma (24), growth-hormone-secreting pituitary tumor (73), symptomatic nocturnal hypertension (09), postcoiling and clipping of an intracranial aneurysm (01), and cerebellar hemangioblastoma (53). One case report describes a patient with apparent hypnic headache and basilar artery dolichoectasia who responded well to verapamil (50). Although there is an association with obstructive sleep apnea (detected in 83% and 73% of cases in two series), there is no temporal relation between oxygen desaturations and headache. Arterial hypertension is also frequently reported in hypnic headache patients, but that relationship also remains unclear (42).

Prognosis and complications

Few prospective studies of the disorder have been conducted. It has been reported that up to 17% of patients with hypnic headache have achieved spontaneous relief (21). Most sufferers, in contrast, seem to have a chronic, unrelenting condition. In one study, 71% of patients continued to have headaches; of those, headache severity decreased in four patients (33%), remained unchanged in seven patients (58%), and increased in one patient. Headache frequency was increased in four patients, decreased in three, and remained unchanged in the others. Spontaneous relief had occurred in only one patient (after 3 years). In contrast, one review describes that nearly 40% of patients reported headache freedom with treatment (42).

An episodic variant of hypnic headache has been reported (44; 61). In these cases, remissions may occur spontaneously or following a course of treatment. In one series, up to 53% of patients entered an episodic course following treatment (41).

Clinical vignette

A 64-year-old man presented with a 7-year history of headaches (26). Before that, he had been headache free and had never had headaches with alcohol consumption. He had begun to have daily headaches that were bioccipital and constant, and the headaches occurred only after he fell asleep. On several occasions, he had fallen asleep during the day and had developed headaches then as well. When present, the headaches were moderately severe, and activity had no effect. Typically, he got up and made a cup of coffee; after drinking the coffee, he went back to sleep. The entire attack typically lasted 90 minutes. He had no nausea, photophobia, phonophobia, or osmophobia. He had no cranial autonomic features. He took no regular medications and had no other medical problems and no family history of headache. On examination, he was well, he weighed 78 kg (172 lb), and his blood pressure was 125/75 mm Hg. On cranial nerve examination, the visual fields were full, and the fundi were normal. His eye movements were normal, and no facial asymmetry was present. He had no trigeminal sensory loss. Limb examination was normal. Gait and coordination were also normal. MRI of the brain with gadolinium was normal. He had overnight blood pressure measurements taken, which were normal. He agreed to an in-hospital trial of single-blinded caffeine 250 mg infusion versus placebo. On the evening of the placebo, he had a headache, and on the caffeine evening, he had no headache and slept through the night. He was diagnosed with hypnic headache and advised to take a strong cup of coffee nightly; at follow-up 8 years later, he remained headache free except on nights when he had skipped the coffee.

Biological basis

Etiology and pathogenesis

The etiology and pathogenesis of this headache syndrome is unclear. The unique features of the syndrome include the exclusive relationship of the headaches, with sleep and the tendency for the headaches to begin in mid to late life. These features imply that this headache disorder may be related to the physiology of sleep (51; 06; 07; 12; 28), and some have proposed a neurodegenerative component, but this has not been proven. Polysomnography in patients with hypnic headache has shown that attacks can occur in both REM and NREM sleep (45; 18; 41; 66; 35). Other documented factors included sleep architecture characterized by low efficiency, an increase in sleep latency, and a markedly decreased percentage of REM sleep (03; 14; 22; 60).

To date, there has been only one report of a patient in whom correction of sleep-disordered breathing with CPAP and nocturnal oxygen supplementation has improved hypnic headache (14). Other studies have found no correlation between the two conditions (14; 60; 44; 45; 41).

Though compelling evidence is lacking, several authors have hypothesized about the possible mechanism of hypnic headache, based on the presumed mechanisms of effective therapies. These theories include causative changes in cerebral blood flow and sympathetic outflow, increased intracranial pressure, and age-related changes in sleep architecture potentially related to alterations in the suprachiasmatic nucleus of the hypothalamus. To investigate this hypothesis, researchers used voxel-based morphometry in 14 patients with hypnic headache and 14 sex-matched controls. Patients with hypnic headache had decreased gray matter volume in the posterior hypothalamus, posterior anterior cingulate, operculum, and frontal and temporal lobes (32). In an earlier study, subjects with hypnic headache were reported to have a decrease in N2 latency and an increased area under the curve of nociceptive blink reflex (31). However, a study of 15 patients with hypnic headache and 15 age- and sex-matched controls found no significant differences in the nociceptive blink reflex and trigeminal pain-related evoked potentials between the two groups (30). There is also a case report of transient hypnic headache accompanying discontinuation of long-term lithium therapy, as well as one describing relief from hypnic headaches following discontinuation of an angiotensin-converting enzyme inhibitor with little to no data in regard to hypnic headache as a manifestation of medication overuse (33). Melatonin concentration changes over 20 hours seem to play no role in the pathogenesis of hypnic headache (54). One hypothesis assumes a potential role of the glymphatic system in hypnic headache (72).

Management

In Raskin’s original monograph of this syndrome, all six patients described had a positive therapeutic response to lithium (62). This observation has been corroborated by several authors (55; 27; 49). The effective dose ranges between 150 and 600 mg daily in single or divided doses to a serum level of 0.5 to 1.0 mmol/L (42). The side effect profile of lithium can be prohibitive, especially in this age group (68; 16). Lithium therapy’s effectiveness has been the best studied, with 35 patients receiving the therapy, 26 of whom received benefit (22). The effects of indomethacin have also been reported, with moderate-to-good results in approximately two-thirds of cases (36; 14; 10; 08; 17). Indomethacin may be particularly beneficial in patients with hemicranial hypnic headaches or in those patients with associated autonomic features. Both indomethacin and lithium must be used with caution in the elderly population and often may be discontinued due to side effects.

Caffeine (either a cup of coffee prior to bedtime or a tablet containing 40 to 60 mg of caffeine) has been shown to have beneficial effects in preventing these nocturnal headaches (16; 34; 74). Surprisingly, this treatment seems to be very well tolerated and does not interfere with patients’ ability to fall asleep. In practice, many clinicians begin with caffeine as a first-line agent. Treatment nonresponders would then be offered the second-line therapies: sustained-release indomethacin 25 to 150 mg at bedtime or lithium 150 to 600 mg daily (40; 42).

There are limited data regarding the effectiveness of other treatments including topiramate (25 to 100 mg/day) (29; 04; 38), oxetorone (60 to 100 mg/day) (19), and sodium ferulate 150 to 300 mg/day) (59); however, there is a suggestion of benefit (39). Other medications felt to be ineffective but with conflicting evidence include tricyclic antidepressants, flunarizine, beta-blockers, verapamil, NSAIDs, prednisolone, other anticonvulsants, acetazolamide, melatonin, benzodiazepines, pizotifen, and methysergide (39; 71). There are reports of onabotulinum toxin for effective management of hypnic headache (46). One case report documented the success of an occipital nerve stimulator in treating chronic, refractory hypnic headache (70), and another patient was treated with greater occipital nerve blocks (63). Yet another case report described amelioration of hypnic headache using a mandibular advancement oral appliance (05). Lack of response has been reported with NSAIDs, oxygen inhalation, acetaminophen, and opioids (57).

Notably, many of the treatments above are from small case series or single reports with a low level of evidence, and many may have conflicting reports (33). In summary, lithium, caffeine, indomethacin, and melatonin were considered effective in 78% of 343 patients (69).

Although many patients experience headaches that are felt to be self-limited, some patients do require acute treatment options. The best efficacy has been demonstrated in caffeine and caffeine-containing analgesics with conflicting evidence in regard to triptans. Nonsteroidal anti-inflammatory (NSAID) agents, acetaminophen, flunarizine, verapamil, topiramate, beta-blockers, acetazolamide, metamizole, opioids, nimesulide, ergotamine, and high-flow oxygen are ineffective or have only very limited evidence of efficacy (42; 02).

References

01: Aldred MP, Raviskanthan S, Mortensen PW, Lee AG. Hypnic headaches in a patient post coiling and clipping of intracranial aneurysm. J Neuroophthalmol 2022;42(1):e415-6. PMID 34224529
02: Al Khalili Y, Chopra P. Hypnic headache. StatPearls. Treasure Island (FL): StatPearls Publishing. StatPearls Publishing LLC, 2022.
03: Arjona JA, Jimenez-Jimenez FJ, Vela-Bueno A, Tallon-Barranco A. Hypnic headache associated with stage 3 slow wave sleep. Headache 2000;40:753-4. PMID 11091296
04: Autunno M, Messina C, Blandino A, Rodolico C. Hypnic headache responsive to low-dose topiramate: a case report. Headache 2008;48(2):292-4. PMID 18081825
05: Bender SD. An unusual case of hypnic headache ameliorated utilizing a mandibular advancement oral appliance. Sleep Breath 2012;16(3):599-602. PMID 21800223
06: Brun J, Claustrat B, Saddier P, Chazot G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995;15:136-9. PMID 7641249
07: Brzezinski A. Melatonin in humans. N Engl J Med 1997;336(3):186-95. PMID 8988899
08: Buzzi MG, Cologno D, Formisano R, Caltagirone C. Hypnic headache responsive to indomethacin: second Italian case. Funct Neurol 2005;20(2);85-7. PMID 15966272
09: Caminero AB, Martin J, Sanchez Del Rio M. Secondary hypnic headache or symptomatic nocturnal hypertension. Two case reports. Cephalalgia 2010;30:1137-9. PMID 20713565
10: Centonze V, D’Amico D, Usai S, Causarano V, Bassi A, Bussone G. First Italian case of hypnic headache, with literature review and discussion of nosology. Cephalalgia 2001;21:71-4. PMID 11298667
11: Cerminara C, Compagnone E, Coniglio A, et al. Hypnic headache in children. Cephalalgia 2011;31(16):1673-6. PMID 22025767
12: Claustrat B, Brun J, Geoffriau M, Zaidan R, Mallo C, Chazot G. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia 1997;17:511-7. PMID 9209772
13: Diener HC, Obermann M, Holle D. Hypnic headche: clinical course and treatment. Curr Treat Options Neurol 2012;14:15-26. PMID 22072057
14: Dodick DW. Polysomnography in hypnic headache syndrome. Headache 2000;40:748-52. PMID 11091295
15: Dodick DW, Jones JM, Capobianco DJ. Hypnic headache: another indomethacin-responsive headache syndrome. Headache 2000;40:830-5. PMID 11135028
16: Dodick DW, Mosek AC, Campbell JK. The hypnic (“alarm clock”) headache syndrome. Cephalalgia 1998;18:152-6. PMID 9595209
17: Dolezil D, Mavrokordatos C. Hypnic headache - a rare primary headache disorder with very good response to indomethacin. Neuro Endocrinol Lett 2012;33(6):597-9. PMID 23160225
18: Dolso P, Merlino G, Fratticci L, et al. Non-REM hypnic headache: a circadian disorder. A clinical and polysomnographic study. Cephalalgia 2007;27(1):83-6. PMID 17212689
19: Donnet A, Lanteri-Minet M. A consecutive series of 22 cases of hypnic headache in France. Cephalalgia 2009;29:928-34. PMID 19250282
20: Eliasson JH, Scher AI, Buse DC, et al. The prevalence of hypnic headache in Iceland. Cephalalgia 2020;40(8):863-5. PMID 27868193
21: Evers S, Goadsby PJ. Hypnic headache: clinical features, pathophysiology, and treatment. Neurology 2003;60:905-9. PMID 12654950
22: Evers S, Rahmann A, Schwaag S, Ludemann P, Husstedt IW. Hypnic headache-the first German cases including polysomnography. Cephalalgia 2003;23:20-3. PMID 12534575
23: Ferretti A, Velardi M, Fanfoni C, et al. Pediatric hypnic headache: a systematic review. Front Neurol 2023;14:1254567. PMID 37638182
24: Garza I, Oas KH. Symptomatic hypnic headache secondary to a nonfunctioning pituitary adenoma. Headache 2009;49(3):470-2. PMID 19178579
25: Gil-Gouveia R, Goadsby PJ. Secondary “hypnic headache”. J Neurol 2007;254(5):646-54. PMID 17404778
26: Goadsby P. Unique migraine subtypes, Rare headache disorders, and other disturbances. Continuum (Minneap Minn) 2015;21(4 Headache):1032-40.** PMID 26252589
27: Gould JD, Silberstein SD. Unilateral hypnic headache: a case study. Neurology 1997;49:1749-51. PMID 9409389
28: Grosberg BH, Lipton RB, Solomon S, Gallaban-Gil K. Hypnic headache in childhood. A case report. Cephalalgia 2005;25(1):68-70. PMID 15606573
29: Guido M, Specchio LM. Successful treatment of hypnic headache with topiramate: a case report. Headache 2006;46(7):1205-6. PMID 16866729
30: Holle D, Gaul C, Krebs S, et al. Nociceptive blink reflex and pain-related evoked potentials in hypnic headache. Cephalalgia 2011c;31(11):1181-8. PMID 21233281
31: Holle D, Naegel S, Gaul C, Krebs S, Gizewski ER. Structural and functional changes in hypnic headache. Cephalalgia 2009;29:2.
32: Holle D, Naegel S, Krebs S, et al. Hypothalamic grey matter volume loss in hypnic headache. Ann Neurol 2011b;69(3):533-9. PMID 21446025
33: Holle D, Naegel S, Obermann M. Hypnic headache. Cephalalgia 2013;33(16):1349-57. PMID 23832130
34: Holle D, Obermann M. Hypnic headache and caffeine. Exp Rev Neurother 2012;12(9):1125-32. PMID 23039391
35: Holle D, Wessendorf TE, Zaremba S, et al. Serial polysomnography in hypnic headache. Cephalalgia 2011a;31:286-90. PMID 20699335
36: Ivanez V, Soler R, Barreiro P. Hypnic headache syndrome: a case with good response to indomethacin. Cephalalgia 1998;18:225-6. PMID 9642499
37: Jimenez-Caballero PE, Gamez-Leyva G, Gomez M, Casado-Naranjo I. [Description of a series of cases of hypnic headache. Differentiation between sexes.] [Article in Spanish] Rev Neurol 2012;54(6):332-6. PMID 22403145
38: Kesserwani H. Hypnic headache responds to topiramate: a case report and a review of mechanisms of action of therapeutic agents. Cureus 2021;13(3):e13790. PMID 33842164
39: Lanteri-Minet M. Hypnic Headache. Headache 2014;54(9):1556-9. PMID 25231430
40: Lanteri-Minet M, Donnet A. Hypnic headache. Curr Pain Headache Rep 2010;14:309-15. PMID 20512536
41: Liang J, Fu J, Yu H, Hsu C, Wang S. Clinical features, polysomnography and outcome in patients with hypnic headache. Cephalalgia 2008;28:209-15. PMID 18254891
42: Liang J, Wang S. Hypnic headache: A review of clinical features, therapeutic options and outcomes. Cephalalgia 2014;34(10):795-805.** PMID 24942086
43: Lindner D, Scheffler A, Nsaka M, Holle-Lee D. Hypnic headache - what do we know in 2022? Cephalalgia 2023;43(3):3331024221148659. PMID 36786376
44: Lisotto C, Mainardi F, Maggioni F, Zanchin G. Episodic hypnic headache. Cephalalgia 2004;24:681-5. PMID 15265058
45: Manni R, Sances G, Terzaghi M, Ghiotto N, Nappi G. Hypnic headache: PSG evidence of both REM- and NREM-related attacks. Neurology 2004;62(8):1411-3. PMID 15111685
46: Marziniak M, Voss J, Evers S. Hypnic headache successfully treated with botulinum toxin type A. Cephalalgia 2007;27(9):1082-4. PMID 17645763
47: Melchior AG, Ayyoub A, Christensen RH, Al-Khazali HM, Amin FM, Ashina H. Epidemiology and clinical features of hypnic headache: a systematic review and meta-analysis. Cephalalgia 2023;43(12):3331024231218389. PMID 38051816
48: Moon HS, Chung CS, Hong SB, Kim YB, Chung PW. A case of symptomatic hypnic headache syndrome. Cephalalgia 2006;26(1):81-3. PMID 16396670
49: Morales-Asin F, Mauri JA, Iniguez C, Espada F, Mostacero E. The hypnic headache syndrome: report of three new cases. Cephalalgia 1998;18:157-8. PMID 9595210
50: Moreira I, Mendonça T, Monteira J, Santos E. Hypnic headache and basilar artery dolichoectasia. Neurologist 2015;20(6):106-7. PMID 26671743
51: Morgan PJ, Barrett P, Howell HE, et al. Melatonin receptors: localization, molecular pharmacology and physiologic significance. Neurochem Int 1994;24:101-46. PMID 8161940
52: Mulero P, Guerrero-Peral AL, Cortijo E, et al. [Hypnic headache: characteristics of a series of 13 new cases and proposal for modification of the diagnostic criteria.] [Article in Spanish] Rev Neurol 2012;54(3):129-36. PMID 22278889
53: Mullally WJ, Hall KE. Hypnic headache secondary to haemangioblastoma of the cerebellum. Cephalalgia 2010;30:887. PMID 20647180
54: Naegel S, Huhn JI, Gaul C, Diener HC, Obermann M, Holle D. No pattern alteration in single nocturnal melatonin secretion in patients with hypnic headache: a case-control study. Headache 2017;57(4):648-53. PMID 27868193
55: Newman LC, Lipton RB, Soloman S. The hypnic headache syndrome: a benign headache disorder of the elderly. Neurology 1990;40:1904-5. PMID 2123309
56: Obermann M, Holle D. Hypnic headache. Expert Rev Neurother 2010;10(9):1391-7. PMID 20839413
57: Patel S. Hypnic headache: a review of 2012 publications. Curr Pain Headache Rep 2013;17(7):346. PMID 23728805
58: Peatfield RC, Mendoza ND. Posterior fossa meningioma presenting as hypnic headache. Headache 2003;43(9):1007-8. PMID 14511280
59: Peng H, Wang L, He B, Giudice M, Zhang L, Zhao ZX. Hypnic headache responsive to sodium ferulate in 2 new cases. Clin J Pain 2013;29(1):89-91. PMID 22688604
60: Pinessi L, Rainero I, Cicolin A, Zibetti M, Gentile S, Mutani R. Hypnic headache syndrome: association of the attack with sleep. Cephalalgia 2003;23:150-4. PMID 12603373
61: Prakash S, Dabhi AS. Relapsing remitting hypnic headache responsive to indomethacin in an adolescent: a case report. J Headache Pain 2008;9:393-5. PMID 18825303
62: Raskin NH. The hypnic headache syndrome. Headache 1988;28:534-6. PMID 3198388
63: Rehmann R, Tegenthoff M, Zimmer C, Stude P. Case report of an alleviation of pain symptoms in hypnic headache via greater occipital nerve block. Cephalalgia 2017;37(10):998-1000. PMID 27257304
64: Ruiz M, Mulero P, Pedraza M, et al. From wakefulness to sleep: migraine and hypnic headache association in a series of 23 patients. Headache 2015;55(1):167-73. PMID 25319633
65: Scagni P, Pagliero R. Hypnic headache in childhood: a new case report. J Paediatr Child Health 2008;44:83-4. PMID 18086044
66: Seidel S, Zeitlhofer J, Wober C. First Austrian case of hypnic headache: serial polysomnography and blood pressure monitoring in treatment with indomethacin. Cephalalgia 2008;28:1086-90. PMID 18498399
67: Silva-Neto RP, Almeida K. Hypnic headache: a descriptive study of 25 new cases in Brazil. Journal Neurol Sci 2014;338:166-8. PMID 24461515
68: Skobieranda FG, Lee TG, Soloman GD. The hypnic headache syndrome: six additional patients. Cephalalgia 1997;17:304-5.
69: Silva-Neto RP, Santos PEMS, Peres MFP. Hypnic headache: a review of 348 cases published from 1988 to 2018. J Neurol Sci 2019;401:103-9. PMID 31075680
70: Son BC, Yang SH, Hong JT, Lee SW. Occipital nerve stimulation for medically refractory hypnic headache. Neuromodulation 2012;15(4):381-6. PMID 22376140
71: Tariq N, Estemalik E, VIj B, Kreigler J, Tepper S, Stillman M. Long-term outcomes and clinical characteristics of hypnic headache syndrome: 40 patients series from a tertiary referral center. Headache 2016;56(4):717-24.** PMID 27015738
72: Toriello M, González-Quintanilla V, Pérez-Pereda S, Fontanillas N, Pascual J. The potential role of the glymphatic system in headache disorders. Pain Medicine 2021;22(12):3098-100. PMID 33839781
73: Valentinis L, Tuniz F, Mucchiat M, et al. Hypnic headache secondary to a growth hormone-secreting pituitary tumor. Cephalalgia 2008;29:82-4.
74: Zdunska A, Cegielska J, Zduński S, Domitrz I. Caffeine for headaches: helpful or harmful? A brief review of the literature. Nutrients 2023;15(14):3170. PMID 37513588

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Hans-Christoph Diener MD PhD

Dr. Diener of the University of Duisburg-Essen received honorariums from Lundbeck and Novartis as an advisory board member.
See Profile

Editor

Stephen D Silberstein MD

Dr. Silberstein, Director of the Jefferson Headache Center at Thomas Jefferson University has no relevant financial relationships to disclose.
See Profile

Former Authors

David Dodick MD (original author), Margarita Sanchez del Rio MD, Michael Ament MD, Wade Cooper DO, Daniel Ackerman MD, and Ilya Bragin MD

Patient Profile

Age range of presentation: 45 to 65+ years
Sex preponderance: female>male;70:30
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Hypnic headache

Associated Disorders

Chronic paroxysmal hemicrania
Cluster headache
Migraine

Differential Diagnosis

migraine
cluster headache
chronic paroxysmal hemicrania
SUNCT
giant cell arteritis
- cerebral tumors
- increased intracranial pressure
- nocturnal hypertension
- obstructive sleep apnea
- other breathing disorders
- depression
- psychiatric disorders with sleep disturbances

Also Relevant

Acute headache: diagnosis
Cluster headache
Migraine
Paroxysmal hemicrania
Sleep and headaches

	Hypnic headache	Migraine	Cluster	Chronic paroxysmal hemicrania	SUNCT
Sex ratio (F:M)	1 to 2:1	3:1	1:3	3:1	5:1
Age of onset	> 50 years	2nd to 3rd decade	20 to 40	20 to 40	55 (39 to 77)
Severity	Mild to moderate	Moderate to severe	Severe	Severe	Severe
Autonomic symptoms	—	+/-	+++	+++	+++
Migrainous symptoms**	+/-	+++	+/-	—	__
Duration	15 to 160 minutes	4 to 72 hours	15 to 180 minutes	2 to 45 minutes	5 to 250 seconds
Unilateral location	Rare	++	+++	+++	+++
Daytime attacks	—	++	++	++	++
Response to indomethacin	+/-	+/-	+/-	+++	-
Typical physical activities	Normal	Bedrest	Agitation	Undefined	Undefined
**Migrainous symptoms (nausea, vomiting, photophobia, phonophobia)

Hypnic headache …

Hypnic headache

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Table 1. Distinguishing Features of Hypnic Headache and Other Headache Syndromes

Diagnostic workup

Management

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Headache associated with intracranial neoplasms

Acupuncture

Migraine in childhood

Headache attributed to head trauma

Migraine: pathogenesis and pathophysiology

Tension-type headache

Benign paroxysmal vertigo

Vagal nerve stimulation for headaches

Hypnic headache

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Table 1. Distinguishing Features of Hypnic Headache and Other Headache Syndromes

Diagnostic workup

Management

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Headache associated with intracranial neoplasms

Acupuncture

Migraine in childhood

Headache attributed to head trauma

Migraine: pathogenesis and pathophysiology

Tension-type headache

Benign paroxysmal vertigo

Vagal nerve stimulation for headaches

This is an article preview.
Start a Free Account
to access the full version.